Short-term continuous infusion of human parathyroid hormone 1-34 fragment is catabolic with decreased trabecular connectivity density accompanied by hypercalcemia in C57BL/J6 mice

被引:53
作者
Iida-Klein, A
Lu, SS
Kapadia, R
Burkhart, M
Moreno, A
Dempster, DW
Lindsay, R
机构
[1] Helen Hayes Hosp, Reg Bone Ctr, W Haverstraw, NY 10993 USA
[2] Helen Hayes Hosp, Clin Res Ctr, W Haverstraw, NY 10993 USA
[3] Scanco USA Inc, Wayne, PA USA
[4] Columbia Univ, Coll Phys & Surg, Dept Clin Pathol, New York, NY USA
[5] Columbia Univ, Coll Phys & Surg, Dept Med, New York, NY USA
关键词
D O I
10.1677/joe.1.06270
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Parathyroid hormone (PTH) stimulates bone resorption as well as bone formation in vivo and in organ culture. The catabolic actions of PTH have been recognized in patients with hyperparathyroidism, or with acute infusion of the N-terminal 1-34 fragment of human PTH (hPTH1-34). Whereas the anabolic actions of daily injection with PTH have been well studied in both humans and mice, the catabolic actions of PTH on murine bone remain to be defined. To do this we sought to create a model with short-term, sustained hyperparathyroidism using osmotic infusion pumps. We treated 10-week-old female C57BL/J6 mice with continuous infusion of hPTH1-34 (8.1 pmol/0.25 mu l per h, equivalent to 40 mu g/kg per day) or vehicle for 2 weeks, using Alzet osmotic pumps. Bone mineral density (BMD), serum total calcium, hPTH1-34, mouse intact PTH (mPTH1-84), osteocalcin and mouse tartrate-resistant acid phosphatase (mTRAP) activity, and microarchitectural variables of the distal femur were measured. Separately, we compared the effects of intermittent daily injection of hPTH1-34 (40 mu g/kg per day) with continuous infusion of hPTH1-34 on BMD and bone markers. Exogenous hPTH1-34 was detected only in the PTH-infused mice. Both intermittent and continuous treatment with hPTH1-34 markedly suppressed endogenous mPTH1-84, but only the latter induced hypercalcemia. Daily PTH injection significantly increased both serum osteocalcin and mTRAP, while continuous PTH infusion showed a strong trend to stimulate rnTRAP, with a slight but non-significant increase in osteocalcin. There were significant differences in BMD at all sites between animals treated with the same daily dose of intermittent and continuous hPTH1-34. Micro-computed tomography (mu CT) analysis of the distal femurs revealed that hPTH1-34 infusion significantly decreased trabecular connectivity density (P < 0.05). Thus, the murine bone response to continuous PTH infusion was quite different from that seen with daily PTH injection. Short-term infusion of hPTH1-34 appears to be a good model to study the mechanisms underlying the catabolic action of PTH in mice.
引用
收藏
页码:549 / 557
页数:9
相关论文
共 35 条
[1]   Human parathyroid hormone 1-34 reverses bone loss in ovariectomized mice [J].
Alexander, JM ;
Bab, I ;
Fish, S ;
Müller, R ;
Uchiyama, T ;
Gronowicz, G ;
Nahounou, M ;
Zhao, Q ;
White, DW ;
Chorev, M ;
Gazit, D ;
Rosenblatt, M .
JOURNAL OF BONE AND MINERAL RESEARCH, 2001, 16 (09) :1665-1673
[2]   Repeated in vivo determinations of bone mineral density during parathyroid hormone treatment in ovariectomized mice [J].
Andersson, N ;
Lindberg, MK ;
Ohlsson, C ;
Andersson, K ;
Ryberg, B .
JOURNAL OF ENDOCRINOLOGY, 2001, 170 (03) :529-537
[3]  
Arnold A, 2002, J BONE MINER RES, V17, pN30
[4]   Primary hyperparathyroidism: new concepts in clinical, densitometric and biochemical features [J].
Bilezikian, JP ;
Brandi, ML ;
Rubin, M ;
Silverberg, SJ .
JOURNAL OF INTERNAL MEDICINE, 2005, 257 (01) :6-17
[5]   Clinical practice - Asymptomatic primary hyperparathyroidism [J].
Bilezikian, JP ;
Silverberg, SJ .
NEW ENGLAND JOURNAL OF MEDICINE, 2004, 350 (17) :1746-1751
[6]   THE CALCEMIC RESPONSE TO PTH IN THE RAT - EFFECT OF ELEVATED PTH LEVELS AND UREMIA [J].
BOVER, J ;
JARA, A ;
TRINIDAD, P ;
RODRIGUEZ, M ;
MARTINMALO, A ;
FELSENFELD, AJ .
KIDNEY INTERNATIONAL, 1994, 46 (02) :310-317
[7]   Effects of an excess and a deficiency of endogenous parathyroid hormone on volumetric bone mineral density and bone geometry determined by peripheral quantitative computed tomography in female subjects [J].
Chen, QX ;
Kaji, H ;
Iu, MF ;
Nomura, R ;
Sowa, H ;
Yamauchi, M ;
Tsukamoto, T ;
Sugimoto, T ;
Chihara, K .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2003, 88 (10) :4655-4658
[8]   RESPONSE OF THE PARATHYROID-GLAND TO INFUSION OF HUMAN PARATHYROID HORMONE-(1-34) [PTH-(1-34)] - DEMONSTRATION OF SUPPRESSION OF ENDOGENOUS SECRETION USING IMMUNORADIOMETRIC INTACT PTH-(1-84) ASSAY [J].
COSMAN, F ;
SHEN, V ;
HERRINGTON, B ;
LINDSAY, R .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1991, 73 (06) :1345-1351
[9]   Parathyroid hormone added to established hormone therapy: Effects on vertebral fracture and maintenance of bone mass after parathyroid hormone withdrawal [J].
Cosman, F ;
Nieves, J ;
Woelfert, L ;
Formica, C ;
Gordon, S ;
Shen, V ;
Lindsay, R .
JOURNAL OF BONE AND MINERAL RESEARCH, 2001, 16 (05) :925-931
[10]   Secondary hyperparathyroidism: Review of the disease and its treatment [J].
de Francisco, ALM .
CLINICAL THERAPEUTICS, 2004, 26 (12) :1976-1993